Literature DB >> 2783704

Binding to Ia protects an immunogenic peptide from proteolytic degradation.

D L Donermeyer1, P M Allen.   

Abstract

A 34 amino acid hen egg-white lysozyme (HEL) peptide was designed and synthesized to investigate if an immunogenic peptide once bound to an Ia molecule becomes proteolytically inaccessible. The determinant recognized by T cells, HEL(52-61) was composed of L-amino acids whereas the 12 amino acid extension on each side of this core were composed of D-epimers. This peptide, HEL(40-73) was resistant to proteolysis, except in the core region, where any cleavage would destroy the determinant. Initially HEL(40-73) was shown to be able to stimulate the HEL specific T cell, 3A9, indicating that an I-Ak molecule can bind and present large peptides that extend beyond the theoretical binding groove. HEL(40-73) was then used to examine the proteolytic sensitivity of determinants recognized by T cells. If HEL(40-73) was treated with chymotrypsin before binding to I-Ak, the determinant was totally destroyed; however, if HEL(40-73) was allowed to first bind to I-Ak, then the determinant became resistant to chymotrypsin cleavage. Thus an Ia molecule can protect a determinant from proteolytic degradation, a finding that has important implications for proposed pathways of Ag processing.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783704

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules.

Authors:  E R Unanue
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak.

Authors:  C A Nelson; R W Roof; D W McCourt; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

3.  Influence of a bacterial extract on antigen presentation and protection against experimental infections.

Authors:  R Fontanges; C Bottex; B Cristau; M F Burckhart
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 4.  Cellular mechanisms of antigen processing and the function of class I and II major histocompatibility complex molecules.

Authors:  C V Harding; E R Unanue
Journal:  Cell Regul       Date:  1990-06

5.  Major histocompatibility class II molecules prevent destructive processing of exogenous peptides at the cell surface of macrophages for presentation to CD4 T cells.

Authors:  Alexei von Delwig; Julie A Musson; Joe Gray; Norman McKie; John H Robinson
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

Review 6.  Antigen presentation: lysoyme, autoimmune diabetes, and Listeria--what do they have in common?

Authors:  Emil Unanue; Craig Byersdorfer; Javier Carrero; Matteo Levisetti; Scott Lovitch; Zheng Pu; Anish Suri
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Proteolytic fragmentation of tetanus toxin by subcellular fractions of JY, a B lymphoblastoid cell line.

Authors:  A Reboul; J Arvieux; J F Wright; M G Colomb
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

8.  A combined method for both endogenous myeloperoxidase and acid phosphatase cytochemistry as well as immunoperoxidase surface labelling discriminating human peripheral blood-derived dendritic cells and monocytes.

Authors:  J M Arkema; I L Schadee-Eestermans; R H Beelen; E C Hoefsmit
Journal:  Histochemistry       Date:  1991

9.  The endo/lysosomal protease cathepsin B is able to process conalbumin fragments for presentation to T cells.

Authors:  G Gradehandt; E Ruede
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

10.  T-cell responses to the trypanosome variant surface glycoprotein are not limited to hypervariable subregions.

Authors:  Taylor R Dagenais; Karen P Demick; James D Bangs; Katrina T Forest; Donna M Paulnock; John M Mansfield
Journal:  Infect Immun       Date:  2008-10-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.